Literature DB >> 10418712

Malignant ovarian germ cell tumours -- a survival and prognostic analysis.

A Ezzat1, M Raja, Y Bakri, J Subhi, M Memon, P Schwartz, R Stuart.   

Abstract

The medical records and histopathology of all ovarian germ cell tumours (OGCT) in a tertiary centre between 1980 and 1996 were reviewed. Response, overall survival (OS), relapse-free survival (RFS) and prognostic factors were analysed. Sixty-seven patients with OGCT were identified and treated, including 33 dysgerminomas, 18 immature teratomas, 10 endodermal sinus tumours, and 6 mixed tumours. Fifty-three patients (79%) received conservative surgery, 24 (36%) had residual disease post-primary surgery, and 43 (64%) had chemotherapy. Complete response was achieved in 62 patients (93%), 4 out of 5 patients who relapsed were successfully salvaged; OS and RFS at 5 years were 89% and 76%, respectively. Advancing stage of disease was the only significant adverse prognostic factor (p = 0.0001 for OS, and 0.0003 for RFS at 5 years). Out of 44 women with the potential to conceive following treatment, there were 16 successful pregnancies. None of the children born subsequent to the chemotherapy were reported to have any congenital abnormalities. The review indicates a high cure rate in OGCT with combined surgery and chemotherapy and that conservative surgery and preservation of fertility are feasible.

Entities:  

Mesh:

Year:  1999        PMID: 10418712     DOI: 10.1080/028418699431988

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  2 in total

1.  Germ Cell Tumor Ovary: an Institutional Experience of Treatment and Survival Outcomes.

Authors:  Manikandan Lakshmanan; Sameer Gupta; Vijay Kumar; Naseem Akhtar; Arun Chaturvedi; Sanjeev Misra; Kavitha Jain; Sudeep Garg
Journal:  Indian J Surg Oncol       Date:  2018-04-10

2.  Socioeconomic disparities affect survival in malignant ovarian germ cell tumors in AYA population.

Authors:  Laura V Bownes; Laura L Stafman; Ilan I Maizlin; Matthew Dellinger; Kenneth W Gow; Adam B Goldin; Melanie Goldfarb; Monica Langer; Mehul V Raval; John J Doski; Jed G Nuchtern; Sanjeev A Vasudevan; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2017-10-06       Impact factor: 2.192

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.